Llwytho...
An Overview of Current Regulatory Requirements for Approval of Biosimilar Insulins
Insulin analog patent expiry is likely to mean that, increasingly, copies of original biopharmaceutical products will be submitted for authorization. Experience with biosimilars in other therapeutic areas suggests that careful regulation and caution are needed. Published guidelines of regulatory aut...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Diabetes Technol Ther |
|---|---|
| Prif Awduron: | , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Mary Ann Liebert, Inc.
2015
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4504437/ https://ncbi.nlm.nih.gov/pubmed/25789689 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/dia.2014.0362 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|